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Abstract
This chapter aims to discuss recent developments in understanding the small 
animal gut microbiome’s relationship with cancer, focusing on animals as well as 
a model for studying humans. Based on multidirectional interactions between the 
microbiome, the environment and the epigenetically/genetically vulnerable host, 
it intends to address the mechanisms by which microorganisms can contribute to 
carcinogenesis describing the roles of the microbiome directly in the pathogenesis 
of the disease through complex interactions between the microbiome and the 
host’s metabolic and immune systems. The feasibility for developing new cancer 
diagnostic and prognostic methodologies plus treatments based on small animals’ 
microbiome profiles are reviewed.
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1. Introduction
Much recent medical research focuses on understanding the influences of 
the microbiome on host health and disease progression such as in inflammatory, 
metabolic, autoimmune and oncologic diseases [1].
In order to introduce the reader to this chapter, it is essential to clarify some 
common terms such as microbiota, metataxonomics, microbiome and metagenome. 
The microbiota is defined as the assemblage of living microorganisms present 
in a certain environment and is composed by bacteria, archaea, fungi, algae and 
small protists [2, 3]. Metataxonomics defines the high-throughput process used to 
taxonomically identify microorganisms in the environment and characterize the 
entire microbiota, creating a metataxonomic tree [2]. The definition of microbiome 
includes not only the microorganisms community, but also their “theatre of activ-
ity” that involves the whole spectrum of molecules produced by them, including 
their structural elements (nucleic acids, proteins, lipids, polysaccharides), metabo-
lites (signaling molecules, toxins, organic, and inorganic molecules), and molecules 
produced by coexisting hosts and structured by the environmental conditions [3]. It 
stands out that all mobile genetic elements, such as phages, viruses, and extracellu-
lar DNA should be included in the term microbiome but are not a part of microbiota 
[3]. Lastly, the term metagenome refers only to the collection of genes and genomes 
of members of a microbiota [2].
In humans, as well as in small animals, these complex communities of microbes 
inhabit predominantly the gastrointestinal tract and oral cavity, but other exposed 
tissues, such as skin, breast, respiratory and urinary tract, can also harbor unique 
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bacterial communities [4–9]. The host microbiota and immune system must 
communicate to maintain a balance between tolerance and activation, otherwise a 
dysbiotic state can be established and may incite or sustain diseases, such as cancer 
[10]. Epidemiological associations of abnormal microbiome with gastric, esopha-
geal, hepatobiliary, pancreatic, lung, colorectal, lymphoma and other human and 
canine cancers have been previously established [11–13].
Neoplastic processes are the leading cause of death in adult dogs [14]. The 
annual cancer incidence rate is 381 per 100,000 dogs with 4 million new cancer 
cases per year, similar to the reported rate in humans (454 per 100.000) with 18 
million new cancer cases annually [15–17]. In these species, naturally occurring 
cancers share many features, including clinical presentation, biological behavior, 
histological features, tumor genetics, and treatment response [18, 19]. Coelho 
and colleagues showed that the dog gut microbiome has a higher taxonomic and 
functional overlap with the human gut microbiome than pigs or mice and con-
cluded that findings in dogs may be predictive of human microbiome results [20]. 
In addition, companion animals represent a special human experimental model in 
microbiomic investigations due to the exchange of microbes between humans and 
their pets [21].
In humans, there are some reviews involving microbiome and cancer, but they 
are scarce in veterinary medicine, with the most reviews covering the microbiome 
gastrointestinal tract and other diseases [22, 23]. The present article reviews the 
current status of comparative oncology approaches in human and small animals in 
the field of microbiome with special focus on carcinogenesis, relationship between 
specific microbiomes as well as the feasibility of new cancer diagnostic tools and 
therapies based on microbiome profiles.
2. Human and small animal microbiomes
The host’s first major exposure to a complex microbiota occurs during birth 
through contact with the maternal microbiome, which represent a primary mecha-
nism for the intergenerational microbiota transfer in mammals and, afterwards, 
bacterial colonization progresses from childhood to adulthood [24]. The microbiota 
development is limited to its niches by the host’s immune system, along with the 
host’s chronological development, providing early modulation of the host’s physi-
ological development and functions of nutrition, immunity and resistance to 
pathogens at all ages [24].
The most important group of organisms in microbiome studies is called the 
dynamic symbionts, whose symbiotic nature may vary along a spectrum from 
mutualism and commensalism to parasitism and amensalism [25]. Usually, 
microbes perform synthetic or catabolic metabolic activity through direct microbe-
host interactions. Catabolism and bioconversion of compounds from the diet make 
nutrients more available to the host through the processes of fermentation, hydroly-
sis, metabolism of drugs and toxins, among others. Some microbiota members can 
synthesize important cofactors or bioactive signaling molecules such as vitamins 
and active amines. In addition, this can trigger changes in the host’s gastrointestinal 
epithelial and immune responses [26].
The combination of factors such as age, genetics, physiological status (includ-
ing innate and adaptive immune system), lifestyle, diet, host environment and 
disease status can result in variation in microbiomes between hosts [27]. Human 
gut microbiota is extremely diverse, with an estimated 1,000 bacterial species in 
the gut with 2,000 genes per species yields an estimate of 2,000,000 genes, which 
is 100 times the commonly estimated 20,000 human genes [27]. In dogs, gut 
3
Small Animals Gut Microbiome and Its Relationship with Cancer
DOI: http://dx.doi.org/10.5772/intechopen.95780
microbiome contains around 1,200,000 genes [20] and recent studies suggest that 
canine and feline gut fecal microbial phylogeny (e.g. predominance of Firmicutes, 
Bacteroidetes, Proteobacteria and Actinobacteria) and functional capacity (e.G. 
major functional groups related to carbohydrate, protein, DNA and vitamin 
metabolism, virulence factors and cell wall and capsule) are similar to those of the 
human gut [28].
3. Microbiome and carcinogenesis
Cancer is a complex disease, in which cumulative genetic, epigenetic physiologi-
cal, immunological and biochemical changes occur incessantly in the tumor tissue, 
contributing to the complexity of the understanding, treatment and management 
of the disease. It is estimated that microorganisms could be associated with 15–20% 
of cancers [29].
As mentioned, the microbiota has an essential role in host health, in which a 
beneficial relationship is established, however, dysbiotic states can trigger several 
diseases, including cancer. Scott and colleagues proposed that in the etiopathogen-
esis of cancer, dysbiosis should be considered a persistent exit of the host micro-
biome from the health-associated homeostatic state (consisting of mutualists and 
commensals), towards a cancer promoting and/or sustaining phenotype (parasitism 
or amensalism) [25]. Currently, metataxonomic and metagenomics studies have 
documented and compared the diversity and abundance of microbes in different 
parts of the body between healthy and diseased patients. In veterinary medicine, 
it has been demonstrated a significant difference in the microbial communities 
in dogs with intestinal and multicentric lymphoma and with colorectal tumors 
comparing to healthy dogs [12, 13, 30]. However, these studies cannot distinguish 
whether some alterations in microbiota are causes or effects of cancer, describing 
only the different microbial communities found among the study groups.
The microbiome causative role has been demonstrated by controlled pre-clinical 
studies utilizing germfree (i.e., devoid of any microbiota) mouse models colonized 
with selected bacteria. For example, several family members of Enterobacteriaceae, 
including Escherichia coli, harbor an island of polyketide synthase (pks) pathogenic-
ity that synthesizes a genotoxin called colibactin [31]. In an experimental study, 
knockout mice for IL-10 were mono-associated with two strains of E. coli that 
were pks + or Δpks (with and without pks, respectively) and treated with pro-
carcinogenic azoxymethane to induce colorectal tumors to demonstrate that pks 
play a causal role in tumorigenesis [31]. All mono-associated pks + mice developed 
invasive carcinoma, in contrast, none of the Δpks mono-associated mice exhibited 
full invasion [31]. This result suggests that the presence of E. coli pks accelerates the 
progression from dysplasia to invasive carcinoma through the genotoxicity of coli-
bactin, an example of pathway of the microbiota-associated carcinogenesis process.
In a recent consensus on the human microbiome role in carcinogenesis, 
expert opinion was that the microbiome is one apex of a tripartite, multidirec-
tional interactome alongside environmental factors (such as diet, obesity) and 
an epigenetically/genetically vulnerable host that combine to cause cancer [25]. 
Gastrointestinal microbiome, which comprises 99% of the microbial mass, not only 
has the greatest both local and long-distance effects on overall health and metabolic 
status, but it is also the best investigated microbiome and serves as a model for 
understanding host–microbiota interactions and disease [32]. Due to its location, 
gut microbiome has been well studied as a contributor to colorectal carcinogenesis 
[33]. Other organs with a well-characterized microbiome include the skin and the 
vagina [34, 35]. The microbiome of each organ is distinct suggesting that effects 
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on inflammation and carcinogenesis are likely to be organ specific. Although many 
organs (e.g. liver and brain), does not have a known microbiome, they may be 
exposed to pathogen-associated molecular patterns (PAMPs) and bacterial metabo-
lites through anatomical links with the gut [32, 36].
For a better understanding of the microbiome role in carcinogenesis it is important 
to recognize that bacteria can be found in the tumor tissue itself, in normal adjacent 
tissue and in tumor sites, such as intestine and genitourinary tract, with overlap 
between these sites (Figure 1). According to Picardo, the microorganisms inside, adja-
cent and distant from the tumor can play a role in cancer development and progression 
and interactions between these microbial populations together with the indirect gut 
microbiome effects have the potential to influence the disease development [37].
At the molecular level, the mechanisms by which microorganisms can contribute 
to carcinogenesis are multiple and varied, which may broadly be categorized into 
genomic integration and genotoxicity (by a direct oncogenic effect of microorgan-
isms and their products); promotion of immunological modifications (which 
disrupts host cancer immunosurveillance through the induction of pro-inflam-
matory and immunosuppressive pathways); and metabolic reprogramming (by 
altering circulating metabolites which become pro-carcinogenic and by stimulating 
the synthesis of trophic factors for cancer cells by the host). Many of these actions 
can harm the host indirectly, as microbes optimizes conditions for their survival 
may result in a final common pathway of prolonged host cell survival, enhanced 
replicative capacity and dedifferentiation [25, 33]. These mechanisms converge to 
hallmarks of cancer [38] and will be described in more detail below.
3.1 Genomic integration
Although the microbiome viral communities have not been studied as much as 
the bacterial community, the virus’s ability to integrate into the host genome is a 
causal mechanism of cancer both in dogs and humans.
A remarkable example is the human papilloma virus (high-risk HPV 16 and 
18) and its association with human cervix cancer. The key event of HPV-induced 
carcinogenesis is the integration of two HPV genes (E6 e E7) into the host genomic 
DNA [39]. In proliferating cells of the basal layer of the uterine cervix, the viral 
Figure 1. 
The relationship between tumor and microbiomes (adapted from Picardo et al., 2019) [37].
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genome persists as episomes, replicates in the suprabasal cells and can infiltrate 
deeper layers [40]. The HPV E6 and E7 genes are regularly present and expressed in 
the tumor tissue [40]. Their expression and the loss of expression of the E2 region 
(which negatively regulates E6 and E7) in the integrated HPV genomes cause the 
disruption of tumor suppressor genes that result in dysregulation of cell growth 
and inhibition of apoptosis [41]. Therefore, the overexpression of these viral genes 
synergistically acts to immortalize host cells, a cancer hallmark.
In dogs, investigations with canine papillomavirus (CPVs) have been limited to 
the association of different CPV genotypes with neoplastic lesions. Up to now, 20 
CPVs types have been reported [42]. In skin, most genotypes of CPVs cause benign 
lesions, such as warts and pigmented/viral plaques or papillomas, which are self-
limiting lesions such as those of oral papillomatosis [43].
Dogs that develop extensive papillomatosis may also be predisposed to oral 
squamous cell carcinoma (SCC) [44]. The detection of CPVs in malignant epithelial 
lesions is increasing in recent years [42, 45, 46]. CPV 1, 2, 3, 7, 12, 16, and 17 have 
been reported to cause epithelium neoplastic transformation. In a retrospective 
study, Thaiwong and colleagues (2018) described 7 dogs bearing benign papillomas 
associated with CPV1 and also the histological evidence of CPV1 causing malignant 
transformation of carcinoma in situ (ISC) and SCC. Later, the same group showed 
the expression of p53 and p16 proteins in cells infected with CPV1 in benign papil-
lomas and lesions that progressed to SCC [42].
In a recent retrospective study, CPVs were successfully detected in 11 skin tissue 
samples and 4 oral tissues obtained from a cohort of canine papillomas and SCCs 
by PCR and through the detection of intralesional viral antigens using immuno-
histochemistry [46]. After sequencing, CPV 1, 2 and 6 were detected in the benign 
lesions, while CPV 9, 15 and 16 were detected in the SCCs, highlighting the risk of 
these genotypes in the induction of epithelial carcinogenesis [46].
The first report of chromosomal integration of CPV 16 into the host genome was 
detected in a sample of squamous cell carcinoma, raising the possibility that CPV 16 
may be a potential type of high-risk canine papillomavirus [47]. However, the CPVs 
oncopathogenesis should be further investigated.
3.2 Genotoxicity
The gut microbiota is mainly composed of bacteria, many of which contain 
toxin-producing strains that can have carcinogenic effects through interfering with 
the cell cycle regulation, cell growth or directly damaging the host’s DNA [48]. 
Pathogenic bacteria strains produce protein toxins to meet their survival needs, 
but these bacterial defense factors perturb the host equilibrium and affect tumor 
suppressor genes or oncogenes and promote host genome instability [49].
Among the large number of bacterial protein toxins, two genotoxins are well 
known for directly affecting the host’s DNA integrity in the host organism target 
cells: cytolethal distending toxin (CDT), which is produced by several gram-
negative pathogenic bacteria (e.g. E. coli, Shigella dysenteriae, Campylobacter jejuni, 
Helicobacter sp.) [50], and colibactin toxin (produced by E. coli strains); both trigger 
double-strand DNA breaks in host cells contributing to carcinogenesis [50, 51]. 
CDT exerts a pro-carcinogenic effect mainly because it presents a DNase activity. 
After binding to the host cell membrane, CDT suffers receptor-mediated endo-
cytosis, proceeds to the endoplasmic reticulum and is translocated to the nucleus, 
where promotes cytotoxicity [50]. Cell CDT intoxication induces DNA damage, 
which results in the stopping of target cells in the G1 and/or G2 phases of the cycle 
and activation of DNA repair mechanisms [50]. Subsequently, normal cells that fail 
to repair the damage and survive the acute phase of CDT intoxication acquire the 
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cancer hallmark of cellular senescence or undergo apoptosis via the DNA host dam-
age checkpoint pathways [52]. This chromosomal instability supports the notion 
that CDT might promote tumor initiation and progression [53].
Colibactin-producing E. coli colonize frequently the colon mucosa of patients 
with human colorectal cancer (CRC) being implicated in carcinogenesis and tumor 
progression [54, 55]. This genotoxin is found in 55–67% of human colorectal cancer 
compared to less than 20% of controls [31, 54]. Understanding of colibactin’s chemi-
cal structure and biological activity is limited, but recent studies have shown that 
these toxins are powerful DNA-damaging agents acting via alkylation and DNA cross-
linking, whose lesions activate the DNA damage checkpoint pathway and cells present 
signs of incomplete DNA repair, G2/M cell cycle arrest and chromosomal instability 
[51, 56]. In addition, colibactin also supports tumor growth by inducing a secretory 
phenotype associated with senescence through growth factors secretion [57].
In veterinary medicine, Feng and colleagues identified E. coli strains encod-
ing colibactin cytotoxic necrotizing factor (CNF) in the rectal swabs and extra-
intestinal samples of macaques, whose can cause clinical and subclinical diseases 
[58]. Genotoxins in companion animals have not been identified so far, but the fecal 
microbiota composition in dogs with colorectal epithelial tumors was different 
from that of control dogs, where Enterobacteriaceae, Bacteroides, Helicobacter, 
Porphyromonas, Streptococcus and Fusobacteriaceae were overrepresented in those 
with tumors [13]. Thus, studies are still needed to identify genotoxins produced by 
bacteria to help understand the carcinogenesis of canine colorectal epithelial tumors.
3.3 Immunological modifications
There is a well-defined bidirectional interaction between the immune system 
and gut microbiome, playing a role in the entire organism physiology [59]. The gut 
microbiota is essential for normal development of innate and adaptive immunity 
at several levels (demonstrated by studies using germ-free mice) and the immune 
system regulates colonization and abundance of microbiome species, as well as the 
response to commensal bacteria [60–63].
The host microbiota and the immune system must communicate to maintain a 
balance between the inflammatory response activation and the immune tolerance 
preservation [64]. For this, the gut bacterial population presents both a protective 
and harmful interface. Unlike opportunistic bacteria, other commensals, such as 
Bifidobacterium infantiles and Faecalibacterium prausnitzii, induce the development 
of regulatory T cells that prevent an inadequate immune response and protect the 
host against intestinal pathogens [65]. A lack of control in pro-inflammatory and 
anti-inflammatory bacteria (causing an imbalance between Th17 and T-regulatory 
cells) establishes a dysbiotic state [65, 66]. Immunological intolerance results in a 
loss of homeostasis that can promote a pro-neoplastic inflammatory environment 
through chronic inflammation, immune evasion and immune suppression [32, 67].
The gut mucosa consists of a single epithelial cell layer with intraepithelial 
lymphocytes that facilitates the interaction of bacterial with immune system. The 
epithelial line contains Paneth cells that secrete anti-microbial molecules and goblet 
cells that secrete mucus to lubricate the intestinal contents and protect the epithe-
lium, while on the skin, keratinocytes regulate the microbes by secreting antibacte-
rial peptides [68]. The lamina propria is below the mucous layer, which contains 
a series of other immune cells (including antigen presenting cells and CD4 + and 
CD8 + T and B cells). This lymphoid tissue is the most important component of 
body’s immune system, capable of influencing immune responses both locally and 
systematically [1]. Microbe is detected using pattern recognition receptors (PRRs) 
represented by Toll-like receptors (TLRs) and NOD-like receptors (NLR) [69].  
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These are widely expressed in intestinal epithelial cells, as well as in intestinal 
macrophages and dendritic cells. PRRs can either control the microbiota through 
antibacterial mediators and thus suppress cancer, or they can promote resistance to 
cell death - a hallmark of cancer [38].
The systemic immune system is prepared (at the epigenetic or transcriptional 
level) to enact a robust response in the presence of pathogenic bacteria leading to 
proinflammatory immune responses or to maintain a non-inflammatory state in the 
absence of threat [70]. A state of disruption of the delicate balance of commensal 
bacteria (dysbiosis), which is characterized by a less stable microbiota, increases 
the potential of opportunistic pathogenic bacteria growth [71]. As seen, dysbiosis 
can promote impaired local, loco-regional and systemic immune responses, being 
able to generate a profound inflammatory state, both locally and systemically. This 
process is outlined in Figure 2.
Figure 2. 
The gut immune system in healthy and dysbiotic microbiome. (A): In healthy dogs, the lamina propria normally 
contains immune cells and secreted cytokines. These include anti-inflammatory mediators (transforming growth 
factor β [TGF-β] and interleukin (IL) -10) that down-regulate immune responses, limit excessive entry of 
intestinal microbiota and defend against pathogens; and noninflammatory defenses such as phagocytosis by 
macrophages, that assist in defending against bacteria entering the lamina propria. A homeostatic balance is 
maintained between regulatory T cells (Treg) and effector T helper cells (Th1, Th2, and Th17). (B): In dogs 
with gut dysbiosis and secondary gut inflammation, several events contribute to increased bacterial exposure, 
including mucus layer disruption, dysregulation of epithelial tight junctions, increased intestinal permeability, 
and increased bacterial adherence to epithelial cells. TLRs initiate the pro-inflammatory stimuli promoting 
innate local immunity through the recognition of pathogen-associated molecular patterns (PAMPs), present in 
bacterial antigens, such as lipopolysaccharides (LPS), peptidoglycans, flagella or unmethylated bacterial DNA 
CpG motifs [72]. The contact of TLRs with PAMPs initiate the innate immune response leading to secretion of 
cytokines and chemokines and increased expression of adhesion molecules that stimulate and facilitate specialized 
cells migration responsible for triggering the innate and, subsequently, the adaptive immune response (tumor 
necrosis factor α (TNF-α), IL-1β, IL-6, IL-12, IL-23, and chemokines) [73]. PAMPs also induce dendritic 
cells (DCs) maturation that travel to mesenteric lymph nodes and present antigen to naive T cells, which 
differentiate into Treg and Th17 cells [68]. Tregs also contribute to intestinal homeostasis through the production 
of immunosuppressive cytokines, such as IL-10. Th17 cells are critical in protecting against bacterial infections 
because stimulates epithelial cells to secrete anti-microbial proteins and recruit neutrophils from the circulation 
to the gut microenvironment, resulting in a cycle of inflammation (adapted from Abraham & Cho, 2009 [68]).
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In many cases, cancer development is correlated with an inflammatory host 
response directly to the pathogen (e.g., Helicobacter pylori and gastric adenocarci-
noma) [74]. But in some cases, cancer progression may be linked to ‘sterile’ inflam-
matory causes that are not directly associated with infectious agents, but arising 
from a response to chronic uncontrolled inflammatory irritation and tissue damage, 
which adds to the malignant transformation [75]. In these cases, the modulatory 
roles in cancer development and progression are attributed to commensal or patho-
genic agents. It has recently become apparent that commensal community members 
of microorganisms are crucially involved in tumor-promoting inflammation, which 
a dysbiotic state stimulates pro-inflammatory properties in the intestinal mucosa 
[75]. One example is intestinal lymphomagenesis associated to gut  microorganism 
changes in host immune and inflammatory responses affecting lymphocytes 
[62, 66, 76–78].
The first study for microbiota-induced inflammatory tumorigenesis demon-
strated that MyD88-dependent signaling controls the expression of several key 
modifier genes of intestinal tumorigenesis and has a critical role in cancer progres-
sion in mouse model of spontaneous intestinal tumorigenesis and in mice treated 
with multiple injections of azoxymethane [79]. This revealed that innate immune 
signaling pathway to intestinal microorganisms is an important factor in intestinal 
tumorigenesis [79].
It was revealed that mucosal associated invariant T (MAIT) cells from human 
breast ducts mediate a selective T-helper 17 cell response to human breast carcinoma 
cells exposed to microbial compounds [80]. This result shows that the presence 
of bacteria in neoplastic epithelial cells can shape the MAIT cells responses by 
inflammatory mediators during breast carcinogenesis [80]. Using a mouse model 
of cutaneous T cell lymphoma (CTCL), it was demonstrated that T cell receptor 
engagement is critical for the T lymphocytes malignant transformation and that 
disease progression is also dependent on microbiota [81].
Studies emphasize that inflammatory response to microbial commensal does 
not occur only in sites of direct contact between the tumor and the microbiota. 
It was demonstrated an increase of intestinal bacteria translocation associated to 
inflammation and fibrosis in human chronic liver diseases and also TLR4 activation 
in non hematopoietic cells in liver carcinogenesis [82]. Thus, there is evidence that 
intestinal microbiota can affect not only local immunity, but also systemic immune 
responses.
In veterinary medicine, fecal microbial communities analysis revealed sig-
nificant lower bacterial diversity and distinct microbial communities in dogs 
with idiopathic inflammatory bowel disease (IBD) compared to healthy control 
dogs [30, 83]. This intestinal dysbiosis was correlated with an increase in E. coli, a 
group of particular interest due to its ability to stimulate inflammatory cytokines 
in human and canine patients with IBD [84–86]. In dogs, the fecal microbiota of 
patients with intestinal lymphoma, multicentric lymphoma and colorectal tumors 
showed a significant difference in its composition when compared to clinically 
healthy dogs microbiota [12, 13, 30]. However, whether these described dysbiotic 
states play a role in carcinogenesis remains to be determined in dogs.
3.4 Metabolic reprogramming
The metabolome is considered the link between genotypes and phenotypes [87]. 
It constitutes a set of metabolites synthesized by a biological system, which can be 
identified by recent “omics” technology called metabolomics, that allows the detec-
tion, identification and quantification of intermediate metabolism and, therefore, it 
can better reflect biological changes in tumorigenesis [88].
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Oscillations in microbiota composition induce metabolic changes that can result 
in host phenotype modifications [89]. Bacterial metabolites production is one of the 
main signaling pathways between host and its microbiome, and metabolic repro-
gramming is a central feature of cancer, enabling cells to generate more energy and 
macromolecules for cancer cell growth, proliferation and division [90].
Microbiome-to-host crosstalk occurs by secreting bacterial metabolites and, 
after absorption, they enter the circulation and reach the target cells, where they 
exert their biological effects [91]. Microbial metabolites are detected in peripheral 
blood (blood metabolome) and feces (fecal metabolome) and have been identi-
fied as biomarkers of several diseases, including cancer [92, 93]. The interaction 
between gut microbiome and fecal and blood metabolome include several mecha-
nisms: a) microbiome can affect gut barrier integrity and alter metabolites absorp-
tion (in this case, the same metabolite is associated with a species/pathway in the 
blood and feces, but the effects directions are opposite); b) direct microbiome-host 
cell interaction results in host systemic modulation (in this case, the species are 
associated with blood metabolites, but not fecal metabolites) [94]. In a metage-
nomic and metabolomic study of 1,004 twins, metabolic pathways were associated 
with 34% of blood and 95% of fecal metabolites and it was estimated that microbi-
ome was involved in a dialog between 71% of feces and 15% of blood metabolites, 
highlighting the interaction importance between microbiome and systemic and 
fecal metabolic environments to identify therapeutic and diagnostic targets [94].
Microbiomes of healthy subjects may share similarities in their metabolic path-
ways and the fecal metabolome provides a functional readout of microbial activity 
and can be used as an intermediate phenotype mediating host-microbiome interac-
tion [29, 30, 95]. Zierer and associates (2018) showed that fecal metabolome largely 
reflects gut microbial composition and fecal metabolic profiling thus is a novel tool 
to explore links among microbiome composition, host phenotypes, and heritable 
complex traits [96].
To facilitate understanding, the most investigated bacterial metabolites and 
enzyme activities can be divided according to the expected effects into more protec-
tive or harmful to gut health and carcinogenesis [97].
3.4.1 Protective metabolites (tumor-suppressive metabolites)
3.4.1.1 Short chain fatty acids (SCFAs)
Fermentation of non-digestible carbohydrates from dietary fiber generates 
SCFAs, such as acetate, butyrate, formate, lactate and propionate [98]. The SCFAs 
have a key role in gut homeostasis maintenance and epithelial integrity including 
anti-inflammatory and antiproliferative tumor suppressive effects [98]. Butyrate 
has been correlated with defense against colon and liver cancer, through its well-
known role in regulating inflammation and autophagy [99]. Butyrate production is 
associated to some Firmicutes, Eubacterium rectale, Roseburia spp., Eubacterium hal-
lii, Coprococcus catus, Faecalibacterium prausnitzii [100]. It is rapidly adsorbed from 
gut lumen and is preferentially used as an energy source by gut epithelial cells, then 
its concentration in the systemic circulation is low. Butyrate is fundamental in epi-
genetic control; once located inside the cell, inhibits activity of histone deacetylases 
(HDACs) in colonocytes and immune cells, which promotes the hyperacetylation of 
histones, allowing transcription factors to bind to DNA and genes to be expressed 
[99]. This has multiple consequences for gene expression and cellular differentia-
tion including: downregulation of pro-inflammatory cytokines (IL-6 and IL-12) 
in colonic macrophages; induction of differentiation of Treg cells that express 
transcription factor FOXP3 (crucial role in controlling intestinal inflammation); 
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and increased acetylation results in higher expression of FOXP3 [99, 101]. As a 
consequence of HDAC inhibition, butyrate triggers the factor activator protein 1 
(AP-1) signaling pathway in the epithelial cell lines that controls cell proliferation 
and apoptosis [102] (Figure 3).
SCFAs modulate several cancer hallmarks, such as cell proliferation, apoptosis 
and level of expression of certain genes (via inhibition of HDACs), mechanisms 
that lead to high anticancer activity (Figure 3). This protection can affect both 
stroma and cancer cells, since they have free fatty acid receptors. It was demon-
strated that microbial fermentation of high-fiber diet increased concentrations of 
butyrate in blood and tumor and significantly decreased tumor growth in mouse 
with lymphoma, suggesting that dietary fiber protects against human lymphoma 
cancer [104]. A metabolomics-proteomics approach in colorectal cancer provided 
a mechanistic link between the M2 isoform of a pyruvate kinase (a direct binding 
target of butyrate) and metabolic remodeling and the antitumorigenic function 
of butyrate, highlighting an applicable approach to uncovering protein targets for 
small molecules with biological functions [105].
Studies in veterinary medicine are very scarce. There is one comparative study 
reporting higher concentrations of β-hydroxybutyrate in blood from dogs with lym-
phoma than in healthy dogs, but further investigations are essential to understand 
the significance of this increase [106]. Another research demonstrated that fecal 
dysbiosis in dogs with acute diarrhea was associated with altered systemic metabolic 
states, in which concentrations of fecal propionic acid were significantly decreased 
compared to healthy dogs [107]. In addition, dogs with inflammatory colorectal 
polyps (ICRP) showed lower amounts of propionic acid and lower proportions of 
Bifidobacterium compared to feces of control dogs suggesting that the association 
Figure 3. 
Modulation of immune signaling through microbial metabolites SCFAs and BA. The metabolic effects directly 
stimulate the cells of the immune system or are relayed by the intestinal epithelium (adapted from Levy et al., 
2019 [103].
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between fecal dysbiosis and fecal SCFA concentrations may contribute to ICRP 
pathogenesis and therapy [108].
3.4.1.2 Phytochemicals
Phytochemicals are bioactive non-nutrient chemical compounds found in fruits, 
vegetables, grains, and other plant foods, which have biological effects associated 
with reduced risk of diseases, including cancer [109]. They can be categorized 
into polyphenols, organosulfur compounds, carotenoids, alkaloids, and nitrogen 
compounds, but the polyphenols are the most studied ones [109].
Their anti-cancer role includes antioxidant effects, modulation of xenobiotic 
detoxification pathways and cell proliferation, apoptosis and inflammation [110]. 
They neutralize reactive oxygen species (ROS) that can damage DNA and predis-
pose to carcinogenesis [97]. A study in human breast cancer cell lines, showed that 
aqueous extract of the Pouteria sapota leaf is rich in phytochemicals with antioxi-
dant properties and significant anti-cancer effects [111]. There is still need for more 
research and clinical trials in humans and dogs that identify and illustrate the action 
of phytochemicals.
3.4.2 Harmful metabolite (oncometabolite)
3.4.2.1 Bile acids (BAs)
“Primary” bile acids are synthesized from cholesterol in the liver as cholic acid 
(CA) and chenodeoxycholic acid (CDCA). When the gallbladder is stimulated after 
a meal, BA flows into the duodenum and proceeds to the ileum to be actively reab-
sorbed, returning back to the liver through the portal bloodstream [112]. About 15% 
of BAs will escape ileum absorption and enter the colon, where the resident microbi-
ota will transform them into secondary BAs (deoxycholic acid, DCA and lithocholic 
acid, LCA) that have pro and anticancer activity [112]. The enzyme responsible for 
this conversion is 7α/β hydroxysteroid dehydrogenase (HSDH), and it is produced 
specially by gram-positive Clostridium species such as Clostridium scindens [113].
Quantitative or qualitative BA pool perturbations may greatly affect several BA 
physiological body functions [113]. The consumption of a high-fat diet changes the 
gut microbiome and increases the level of DCA, that can promote carcinogenesis 
in colorectal and liver cancer [114, 115]. Pathways linking BAs to carcinogenesis 
involve the generation of ROS and reactive nitrogen species (RNS), which cause 
DNA damage, apoptose and epigenetic changes [112]. Moreover, BAs also exert 
strong antimicrobial activities, as they damage bacterial cell membranes, contribut-
ing to changes in gut microbiota (Figure 3). These mechanisms can also be second-
ary to environmental stimuli (particularly in the context of obesity) and their 
relationships with human cancer have been recognized as critical in gastrointestinal 
tract, prostate and breast tissues [116–118].
There are some publications covering changes in the fecal BA profile in canine 
chronic inflammatory enteropathy and extrahepatic congenital portosystemic 
shunts, but not in carcinogenesis [119–121].
4. Gut microbiome and therapeutic application
The growing understanding of the microbiome’s role in carcinogenesis has 
allowed the microbiome influence to be linked to the effectiveness of cancer 
therapies. Microbiome modulation strategies can affect cancer treatment through 
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inactivation or activation of chemotherapeutic agents, modification of immune 
responses and interference with side effects [72]. This relationship is bilateral, in 
which the systemic cancer therapy influences gut microbiota, and gut microbiota 
influences cancer treatment [122]. Recent publications indicate the gut microbiome 
manipulation as a new treatment tool or to improve the response to cancer therapy. 
Some of the proposed mechanisms will be discussed below.
4.1 Roles of microbiome in cancer therapy
4.1.1 Chemotherapy
Iida et al. (2013) demonstrated that microbiota impairs disruption response of 
subcutaneous tumors to platinum derived chemotherapeutic agents. Tumor-bearing 
mice that lacked microbiota showed therapy efficacy reduction, given that micro-
biota was important for activating the innate immune response [123]. In another 
study, administration of Ruminococcus gnavus (bacterial strain depleted by treat-
ment with cisplatin) was able to partially restore intestinal mucosa integrity and 
reduce systemic inflammation in mice treated with cisplatin [124]. Results indicate 
that reconstitution of gut microbiome can help healing intestinal epithelium in 
patients treated with chemotherapy.
On the other hand, Viaud et al. (2013) demonstrated that gut microbiota helps 
shape anti-cancer immune response of cyclophosphamide (CTX). Using mouse 
models, it was demonstrated that cyclophosphamide alters intestine microbiota 
composition and induces translocation of selected species into secondary lym-
phoid organs, resulting in Th17 cells maturation promoting an adaptive immune 
response against tumors [125]. Daillere et al. (2016) identified Enterococcus hirae 
and Barnesiella intestinihominis species involved in tumor immunosurveillance 
during cyclophosphamide therapy; E. hirae translocates from gut to lymph nodes 
inducing Th1 and Th17 responses mandatory for anti-tumor activity of CTX, while 
B. intestinihominis increases systemic Th1 and CD8 + cytotoxic T cells, which were 
associated with an increase of IFN-y-producing γ δ tumor infiltrating-lymphocytes 
(TILs) contributing also for anti-tumor CTX effect [126]. Therefore, cyclophospha-
mide immunomodulatory effects require a functional microbiome.
Chemotherapy efficacy can also be impacted by intratumoral bacteria. Geller 
et al. (2017) showed, in a colon cancer mouse model, that Gammaproteobacteria 
can metabolize chemotherapeutic gemcitabine into an inactive form inducing 
chemotherapy resistance and that this effect was reversed by antibiotic ciprofloxa-
cin. Interestingly, about 76% of human pancreatic ductal adenocarcinomas were 
positive for bacteria, mainly Gammaproteobacteria [127]. Perhaps the treatment for 
this tumor type may be improved by adding antibiotics to the chemotherapy.
Chemotherapy-induced diarrhea (CD) is a frequent adverse event in dogs, in 
which changes in gut microbiota appear to play a key role. A recent study of 60 
dogs undergoing chemotherapy supported the administration of smectite, a natural 
medical clay, widely used in acute diarrhea treatment in humans, as a first-line 
treatment of CD in dogs. Interestingly, smectite has anti-inflammatory properties 
to decrease intestinal bacterial translocation and stabilize intestinal microbiome 
[128]. However, studies associating microbiome and effectiveness of chemotherapy 
are still scarce in veterinary medicine.
4.1.2 Immunotherapy
Several studies have shown a complex crosstalk between bacteria and immune 
host response in the anti-tumor battle. For example, Paulos et al. (2007) reported 
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that total body irradiated mice showed a more efficient anti-tumor response to adop-
tively transferred tumor-specific CD8+ T cells against melanoma after gut microbial 
translocation to mesenteric lymph nodes. They observed that the radiation induced 
the release of microbial LPS and activated innate immune response by TLR4 stimula-
tion and then increased anti-tumor CD8+ T cells, while reduction of host microflora 
using antibiotics, neutralization of serum LPS using polymyxin B, or removal of LPS 
signaling were associated with a decrease of anti-tumor response [129].
There is also evidence that gut microbiome modulates efficacy of immune 
checkpoint inhibitors (CIs), that are monoclonal antibodies with inhibitory effect 
to specific receptors on T cells and tumor cells, blocking signaling pathways that 
negatively modulate immune system, allowing specific T cells to promote destruc-
tion of cancer cells [130]. Those receptors include cytotoxic T lymphocyte-associ-
ated antigen 4 (CTLA-4), programmed death 1 protein (PD-1), and programmed 
death-ligand 1 (PD-L1) [131].
It was demonstrated that oral administration of Bifidobacterium in mice with 
melanoma was associated with the same degree of antitumor effects as in those 
mice that received therapy with PD-L1 antibodies, and the combination of both 
treatments almost abolished tumor growth [132]. In addition, a report of human 
gut microbiome metagenomic profiling in 39 metastatic melanoma patients treated 
with anti-PD1 and/or anti-CTLA-4 immunotherapy identified that those who 
respond to all types of CIs were enriched for Bacteroides caccae, enhancing that 
microbiota may modulate cancer immunotherapy [133]. These correlations have not 
yet been demonstrated in dogs.
4.2  Therapeutic manipulation of microbiome and its relevance to cancer 
therapies response
Given the increasing evidence on the significant role that microbiome can play 
in cancer, microbiota modulation represents a new therapeutic potential capable of 
altering disease development. These therapies aim to change the microbial com-
munity associated with dysbiosis for those associated with health. In small animals, 
microbiome manipulations are often described as part of gastrointestinal diseases 
treatment [134]. Mainly as an adjuvant treatment for cancer, these interven-
tions and their effectiveness are not well established and have only recently been 
described in literature. The following will discuss some ways in which microbiome 
can be modified:
4.2.1 Prebiotics and symbiotics
Prebiotics are specific chemicals, capable of promoting growth of a selective 
group of bacteria and their specific metabolites and thus modulating microbiota 
in a beneficial way, which may help on anti-tumor treatment [135]. These are 
non-digestible or absorbable dietary fibers and include fructans (oligofructose and 
inulin), nonstarch polysaccharides found in some cereal grains, algae, disaccharides 
(lactulose), and polysaccharides including fructooligosaccharides (FOS) [22].
According to Villegér and colleagues, the effect of prebiotics depends on the 
presence of beneficial bacteria in the host’s intestines [33]. Thus, the combination of 
probiotics and prebiotics, known as symbiotic, looks promising. Dietary treatment 
with inulin or oligofructose has been demonstrated to selectively stimulate growth 
of specific bacterial taxa and alter SCFA levels within the gut [136]. Moreover, these 
prebiotics reduced the incidence of mammary tumors in rats, significantly potenti-
ated chemotherapy effects as well as RT [136]. The perioperative administration of 
symbiotics, probiotics (strains Lactobacillus and Bifidobacterium) and prebiotic 
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(fructooligosaccharides), reduced postoperative mortality and complication rates in 
cancer patients undergoing surgery [137].
The effects of prebiotics were evaluated in dogs, but without focusing on the 
benefits of cancer treatment. A recent study evaluated the effects of prebiotics in 
different concentrations in healthy adult dogs and concluded that the galactooligo-
saccharide prebiotic at 1.0% improved the immunity of healthy dogs [138]. Inulin 
intervention resulted in a modulation of intestinal bacteria, increase of fecal SCFA 
and BA in dogs. Given that some studies showed similar dysbiotic states between 
dogs and humans with cancer [12, 13, 37], it seems relevant that the new approaches 
to increase anticancer therapy efficiency should include the potential benefits of 
prebiotic supplementation for both dogs and humans.
4.2.2 Probiotics
Probiotics refers to live bacteria that can be orally administered and confer health 
beneficial when delivered in adequate amounts [139]. Probiotics colonize the gut tem-
porarily and act modifying colonic environment. Different mechanisms are involved 
in probiotics protective role: increase in barrier function, epithelial tight junctions 
integrity, immune response modulation, anti-inflammatory cytokines production, 
pathogenic bacteria growth inhibition by antimicrobial and antitoxin compound 
production (i.e. SCFA), and production of enzymatic activities and/or beneficial 
metabolites to the host [140]. A recent systematic review and meta-analysis investi-
gated probiotics efficacy and safety in patients diagnosed with cancer and concluded 
that probiotics may be beneficial but further studies are still required [141].
The strains of Lactobacillus and Bifidobacterium are most frequently reported 
in studies with probiotics. The “protective” effect against colorectal cancer was 
demonstrated after oral supplement containing Lactobacillus helveticus in mice 
with colonic cancer, in which tumor growth rate and degree of hyperplasia were 
reduced [142]. These effects were secondary to suppression of NF-κB, increased 
of anti-inflammatory IL-10 and decreased IL-17-producing T cells [142]. In addi-
tion, administration of L. acidophilus in mice with breast tumors reduced tumor 
growth due to altered cytokine production and, in a murine melanoma model, the 
therapy with aerosolized L. rhamnosus promoted immunity against lung metastases, 
identifying a role for a probiotic cancer “preventing” [143, 144].
Probiotics can also affect patient “outcomes”. In a prospective randomized 
study, after transurethral resection of bladder cancer, the group of patients who 
received oral supplementation with L. casei associated with intravesical epirubicin 
application had a 3-year recurrence-free survival rate significantly higher than in 
the isolated chemotherapy group [145]. In addition, some studies demonstrate the 
action of probiotics on treatment-related toxicity. L. rhamnosus decreased diarrhea 
and abdominal discomfort in patients with colon cancer treated with 5-fluorouracil 
chemotherapy [146]. Symbiotics (a combination of Bifidobacterium breve and L. 
casei) during neoadjuvant chemotherapy in esophageal cancer patients reduced the 
occurrence of adverse events (diarrhea, neutropenia and lymphopenia) [147].
However, caution should be exercised in their use, since the composition of 
commercially available probiotics have been inadequately studied, as well as their 
long-term impact on intestinal microbiota and general health [135]. When investi-
gating the use of pre- and probiotics in dogs, scientific evidence of their benefit is 
scarce, especially in cancer. Furthermore, the knowledge about appropriate doses 
and compositions is small in companion animals [148]. Studies suggest that they 
may have beneficial effects on canine IBD. In a prospective randomized study, 34 
IBD dogs received prednisone with or without multi-strain probiotic. Both treat-
ments increased the numbers of total bacteria and were associated with rapid 
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clinical remission but not improvement in histopathologic inflammation [149]. A 
protective effect of multi-strain probiotic (strains of Lactobacillus, Bifidobacterium 
and Streptococcus) was also observed in dogs with IBD compared with a control 
group (treated with metronidazole and prednisolone), with a significant decrease 
in clinical and histological scores [150].
A recent study showed that probiotics consumption (L. casei, L. plantarum and 
Bifidobacterium) in healthy dogs of different age groups, significantly increased 
beneficial intestinal bacteria (Lactobacillus and Faecalibacterium prausnitzii) and 
decreased potentially harmful bacteria (E. coli and Sutterella stercoricanisin) mostly 
in elderly dogs, suggesting that probiotic treatment improves host health and 
immunity [151].
4.2.3 Fecal microbiome transplantation (FMT)
In FMT, feces are transferred from a healthy donor to the intestinal tract of 
a diseased recipient [30]. FMT may be delivered via colonoscopy, enema or oral 
administration, with equal clinical efficacy [152]. The beneficial mechanisms of 
FMT are still unknown. Nowadays, FMT has been used in resistant Clostridium 
difficile treatment with high response rates [153]. Contrary to gastrointestinal (GI) 
diseases, application of FMT in cancer is still limited and data was obtained mainly 
in animal models. The reconstitution of germ-free mice with fecal material from 
patients with melanoma responsive to anti-PD-L1 and to anti-PD-1 therapies led 
to better tumor control in contrast to those that received faces from unresponsive 
patients [154, 155].
The use of FMT in veterinary medicine was studied mostly in dogs with GI 
diseases, such as in parvovirus-infected puppies and patients with diarrhea due to 
IBD and C. perfringens, and it was associated with faster resolution of clinical signs 
[156]. For a deep learning regarding the FMT effects in veterinary non-oncological 
diseases and the potential applications of FMT in animals, including therapeutic, 
prophylactic and immunogenic uses, the reader may consult Niederwerder (2018) 
publication [157].
5. Conclusions
Host-microbiota interactions are crucial in human and animal health and disease 
development, yet microbiota function and dynamics during disease states are only 
partially understood. There is growing evidence supporting that immunoregula-
tory and anti-inflammatory effects of gut and tumor microbiota are essential in 
the battle of cancer. However, most studies were performed in preclinical models, 
which have many pitfalls in regard of spontaneous cancer research urging the need 
for clinical studies benefiting both species.
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